MA54533A - Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation - Google Patents

Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation

Info

Publication number
MA54533A
MA54533A MA054533A MA54533A MA54533A MA 54533 A MA54533 A MA 54533A MA 054533 A MA054533 A MA 054533A MA 54533 A MA54533 A MA 54533A MA 54533 A MA54533 A MA 54533A
Authority
MA
Morocco
Prior art keywords
compositions
methods
streptococcus pneumoniae
protein conjugates
pneumoniae polysaccharide
Prior art date
Application number
MA054533A
Other languages
English (en)
Inventor
Chitrananda Abeygunawardana
Yadong Adam Cui
Romulo Ferrero
Jian He
Luwy Musey
Tanaz Petigara
Julie M Skinner
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA54533A publication Critical patent/MA54533A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA054533A 2018-12-19 2019-12-17 Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation MA54533A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862781835P 2018-12-19 2018-12-19
US201962853331P 2019-05-28 2019-05-28

Publications (1)

Publication Number Publication Date
MA54533A true MA54533A (fr) 2022-03-30

Family

ID=69173427

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054533A MA54533A (fr) 2018-12-19 2019-12-17 Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation

Country Status (25)

Country Link
US (5) US11642406B2 (fr)
EP (1) EP3897705A2 (fr)
JP (4) JP7275277B2 (fr)
KR (2) KR20240169145A (fr)
CN (2) CN119971019A (fr)
AU (2) AU2019401535B2 (fr)
BR (1) BR112021011961A8 (fr)
CL (1) CL2021001572A1 (fr)
CO (1) CO2021008023A2 (fr)
CR (1) CR20210333A (fr)
DO (1) DOP2021000127A (fr)
EC (1) ECSP21044606A (fr)
GE (2) GEP20247633B (fr)
IL (1) IL283896B1 (fr)
JO (1) JOP20210148A1 (fr)
MA (1) MA54533A (fr)
MX (1) MX2021007496A (fr)
NI (1) NI202100050A (fr)
PE (1) PE20211888A1 (fr)
PH (1) PH12021551448A1 (fr)
SG (1) SG11202106541WA (fr)
TW (1) TWI788610B (fr)
UA (1) UA130252C2 (fr)
WO (1) WO2020131763A2 (fr)
ZA (1) ZA202104162B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
CA3050120A1 (fr) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Amelioration de l'immunogenicite de conjugues de polysaccharide de streptococcus pneumoniae et de proteine
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050814A1 (fr) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Polysaccharides antipneumococciques et leur utilisation dans des conjugués immunogènes polysaccharide-protéine porteuse
US20210177957A1 (en) 2017-12-06 2021-06-17 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2019212842A1 (fr) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Procédés de production de conjugués protéine porteuse-polysaccharide capsulaire de streptococcus pneumoniae à partir de lyosphères
CN112041435B (zh) 2018-04-30 2024-05-31 默沙东有限责任公司 提供冻干的突变白喉毒素在二甲基亚砜中的均质溶液的方法
CN112074293B (zh) 2018-04-30 2025-07-11 默沙东有限责任公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
KR20240169145A (ko) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
KR20220102871A (ko) * 2021-01-14 2022-07-21 (주)셀트리온 다가 폐렴구균 다당류-단백질 접합체를 포함하는 면역원성 조성물
TW202245835A (zh) * 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
JP2025537898A (ja) * 2022-11-22 2025-11-20 ファイザー・インク コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
WO2024238731A1 (fr) 2023-05-18 2024-11-21 Merck Sharp & Dohme Llc Composés et formulations d'adjuvant utiles dans des vaccins pneumococciques
WO2025174398A1 (fr) 2024-02-14 2025-08-21 Merck Sharp & Dohme Llc Vaccins pneumococciques conjugués 26-valents et leurs méthodes d'utilisation

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
EP0027888B1 (fr) 1979-09-21 1986-04-16 Hitachi, Ltd. Interrupteur à semiconducteur
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0378881B1 (fr) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Peptides synthétiques et leur utilisation comme support universel pour la préparation de conjugués immunogènes convenant au développement de vaccins synthétiques
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FI920131A0 (fi) 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
CA2059692C (fr) 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
CA2059693C (fr) 1991-01-28 2003-08-19 Peter J. Kniskern Antigenes polysaccharides de streptococcus pneumoniae
WO1993015760A1 (fr) 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Structure immunogene a double vecteur
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ES2130265T3 (es) 1992-05-06 1999-07-01 Harvard College Region de union al receptor de la toxina difterica.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
PT616034E (pt) 1993-03-05 2005-02-28 Wyeth Corp Plasmideo para a producao de proteina crm e toxina da difteria
DE69433341T2 (de) 1993-09-22 2004-04-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE241384T1 (de) 1995-03-22 2003-06-15 Jackson H M Found Military Med Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
WO1996039182A1 (fr) 1995-06-06 1996-12-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Produit d'assemblage immunogene a double porteur
PT942983E (pt) 1996-10-31 2007-02-28 Human Genome Sciences Inc Antigénios e vacinas de streptococcus pneumoniae
KR19980067137A (ko) 1997-01-31 1998-10-15 박원훈 알긴산염 초미세과립구를 이용한 폐렴구균 감연중에 대한 백신
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP1165796A2 (fr) 1999-04-09 2002-01-02 Techlab, Inc. Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
CZ2003154A3 (cs) 2000-06-20 2003-06-18 Shire Biochem Inc. Antigeny streptokoka
OA12302A (en) 2000-06-29 2003-10-24 Glaxosmithkline Biolog Sa Multivalent vaccine composition.
DK1355918T5 (da) 2000-12-28 2012-02-20 Wyeth Llc Rekombinant beskyttelsesprotein af streptococcus pneumoniae
MXPA03009415A (es) 2001-04-16 2004-01-29 Wyeth Corp ESTRUCTURAS NOVEDOSAS DE LECTURA ABIERTA DE STREPTOCOCCUS PNEUMONIAE QUE CODIFICAN ANTIGENOS DE POLIPePTIDOS Y USOS DE LAS MISMAS.
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
WO2003009869A1 (fr) 2001-07-26 2003-02-06 Chiron Srl. Vaccins comprenant des adjuvants aluminium et histidine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
NO346070B1 (no) 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
PT1601689E (pt) 2003-03-13 2008-01-04 Glaxosmithkline Biolog Sa Processo de purificação para citolisina bacteriana
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
AU2003901717A0 (en) 2003-04-10 2003-05-01 Western Sydney Area Health Service Identification of streptococcus pneumoniae serotypes
US20090317412A1 (en) 2004-06-04 2009-12-24 Alexander Jeffery L Induction of an immune response against streptococcus pneumoniae polyaccharides
EP1828230A2 (fr) 2004-12-16 2007-09-05 Stichting Top Institute Food and Nutrition Nouvel efficient procédé de production de polysaccharides capsulaires de bactéries gram-positives pathogènes par expression hétérologue et sécrétion de polysaccharides complexes dans des bactéries gram-positives non-pathogènes et non-invasives
EP1866342B1 (fr) 2005-04-08 2018-11-21 Wyeth LLC Separation de contaminants a partir de polysaccharide de streptococcus pneumoniae par manipulation du ph
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102378962B1 (ko) 2005-04-08 2022-03-28 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
US7764278B2 (en) 2005-06-30 2010-07-27 Seiko Epson Corporation Integrated circuit device and electronic instrument
CN103251940A (zh) 2005-12-22 2013-08-21 葛兰素史密丝克莱恩生物有限公司 疫苗
AU2006336520B2 (en) 2005-12-28 2011-09-15 The Uab Research Foundation Pneumococcal serotypes
US8481054B2 (en) 2005-12-28 2013-07-09 The UAB Foundation Pneumococcal serotypes
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP2056871B1 (fr) 2006-08-07 2017-11-15 President and Fellows of Harvard College Vaccins à base de matrice protéique et procédés de fabrication et d'administration de tels vaccins
CN102648979B (zh) 2006-10-10 2014-05-14 惠氏公司 肺炎链球菌3型多糖的纯化
PL2436700T3 (pl) 2007-03-23 2018-12-31 Wyeth Llc Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
US8540955B2 (en) 2007-07-10 2013-09-24 Wyeth Llc Process for producing aluminum phosphate
CN102257155B (zh) 2008-12-18 2016-03-02 惠氏有限责任公司 控制肺炎链球菌血清型19a多糖分子量的方法
AU2009335824B2 (en) 2008-12-18 2013-07-04 Wyeth Llc Method for controlling Streptococcus pneumoniae polysaccharide molecular weight using carbon
CN101590224A (zh) 2009-06-30 2009-12-02 广州精达医学科技有限公司 高效14价肺炎球菌结合疫苗
AU2010292195A1 (en) 2009-09-09 2012-03-15 Matrivax Research & Development Corp. Protein matrix vaccines of improved immunogenicity
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP3170508B1 (fr) 2010-06-04 2019-11-13 Wyeth LLC Formulations vaccinales
AR084158A1 (es) 2010-12-10 2013-04-24 Merck Sharp & Dohme Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
CN102068690A (zh) 2010-12-31 2011-05-25 北京民海生物科技有限公司 多价肺炎球菌荚膜多糖结合疫苗及其制备方法
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
ES2728653T3 (es) 2011-05-18 2019-10-28 Matrivax Inc Composiciones vacunales con una matriz proteica que incluye policationes
EP2718306A1 (fr) 2011-06-13 2014-04-16 Merck Sharp & Dohme Corp. Procédés de purification de formes endogènes ou mutantes de la toxine diphtérique
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN103623401A (zh) 2012-08-23 2014-03-12 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法
CN103656632B (zh) 2012-09-24 2016-01-13 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖组合物、其制备方法及应用
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR101980989B1 (ko) 2012-12-20 2019-05-21 화이자 인코포레이티드 당접합 방법
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN104069488A (zh) 2013-03-29 2014-10-01 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法
MX371453B (es) 2014-01-21 2020-01-29 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
CA3206112A1 (fr) 2014-01-21 2015-07-30 Pfizer Inc. Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues et leurs utilisations
JP6612260B2 (ja) 2014-01-21 2019-11-27 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖およびそのコンジュゲート
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
IL255106B2 (en) 2015-05-04 2023-04-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses
PE20180460A1 (es) 2015-06-08 2018-03-06 Serum Inst Of India Private Ltd Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos
ES2857474T3 (es) 2015-06-23 2021-09-29 Biological E Ltd Vacuna conjugada neumocócica multivalente
WO2017011338A1 (fr) 2015-07-10 2017-01-19 President And Fellows Of Harvard College Couplage à médiation par la sortase de conjugués protéine-polysaccharide immunogène et leur utilisation
EP3325008B1 (fr) 2015-07-21 2025-09-10 Pfizer Inc. Compositions immunogènes contenant des antigènes saccharidiques capsulaires conjugués, kits comprenant ces compositions et leurs utilisations
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
RU2021135165A (ru) 2015-11-17 2021-12-29 Пфайзер Инк. Среды и способы ферментации для производства полисахаридов в бактериальной клеточной культуре
WO2017085586A1 (fr) * 2015-11-20 2017-05-26 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
EP4488286A3 (fr) * 2016-03-31 2025-04-02 Pogona, Llc Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
WO2017220753A1 (fr) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugué polysaccharide pneumococcique-protéine
CN105999254A (zh) 2016-06-27 2016-10-12 北京智飞绿竹生物制药有限公司 含2型和12f血清型的15价肺炎球菌结合物组合疫苗
WO2018009906A1 (fr) 2016-07-08 2018-01-11 President And Fellows Of Harvard College Conjugués cellules entières – protéines, et procédés de fabrication de ces derniers
WO2018022573A1 (fr) 2016-07-27 2018-02-01 Sharp Laboratories Of America, Inc. Procédés et appareil de télécommunication sans fil utilisant une étiquette de valeur d'information système
MY199342A (en) 2016-08-05 2023-10-24 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102437120B1 (ko) 2016-08-05 2022-08-25 사노피 파스퇴르 인코포레이티드 다가 폐렴구균 다당류-단백질 접합체 조성물
JOP20190038B1 (ar) 2016-09-06 2023-09-17 Lg Chemical Ltd تركيب اقتراني من السكر المتعدد لكبسولة بكتيريا المكورات الرئوية وبروتين حامل واستخداماته
JP2019529497A (ja) * 2016-09-30 2019-10-17 バイオロジカル イー リミテッド 多糖類−タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物
KR20180043122A (ko) 2016-10-19 2018-04-27 동국대학교 산학협력단 신규링커를 통한 폐렴구균 다당류-단백질 접합체 백신 및 이의 용도
WO2018080213A1 (fr) 2016-10-28 2018-05-03 주식회사 엘지화학 Composition immunogène multivalente ayant un titre d'igg augmenté, et son utilisation
CN108144056A (zh) 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 多价肺炎球菌多糖结合疫苗及其制备方法
DK3562503T3 (da) * 2016-12-30 2025-05-26 Vaxcyte Inc Polypeptid-antigen-konjugater med ikke-naturlige aminosyrer
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
CA3050120A1 (fr) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Amelioration de l'immunogenicite de conjugues de polysaccharide de streptococcus pneumoniae et de proteine
US20200054740A1 (en) 2017-02-24 2020-02-20 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
WO2019050818A1 (fr) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Procédés de formulation de polysaccharides pneumococciques pour conjugaison à une protéine porteuse
US11219680B2 (en) 2017-02-24 2022-01-11 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
EP3585427A4 (fr) 2017-02-24 2020-12-30 Merck Sharp & Dohme Corp. Procédés d'amélioration de la filtrabilité de réactions de polysaccharide conjugué à une protéine
WO2018169303A1 (fr) 2017-03-15 2018-09-20 주식회사 엘지화학 Composition vaccinale polyvalente contre streptococcus pneumoniae
CN107929728A (zh) 2017-04-19 2018-04-20 武汉博沃生物科技有限公司 一种肺炎球菌蛋白疫苗及其制备方法
EP3634481A4 (fr) 2017-06-10 2021-07-21 Inventprise, LLC. Vaccins conjugués multivalents avec des polysaccharides conjugués bivalents ou multivalents qui confèrent une immunogénicité et une avidité améliorées
CN109091668A (zh) 2017-06-20 2018-12-28 浙江博和瑞达生物科技有限公司 16价肺炎链球菌结合疫苗组合物
US20200360500A1 (en) 2017-08-16 2020-11-19 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050814A1 (fr) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Polysaccharides antipneumococciques et leur utilisation dans des conjugués immunogènes polysaccharide-protéine porteuse
WO2019070994A1 (fr) 2017-10-04 2019-04-11 Liffey Biotech Limited Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
JP2021501144A (ja) 2017-10-25 2021-01-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アジュバントワクチン
US20210177957A1 (en) 2017-12-06 2021-06-17 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP2019118051A (ja) 2017-12-27 2019-07-18 株式会社デンソー 表示処理装置
CN108159408A (zh) 2017-12-29 2018-06-15 云南沃森生物技术股份有限公司 一种多价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
CN108245674A (zh) 2018-01-18 2018-07-06 北京智飞绿竹生物制药有限公司 一种多价肺炎球菌结合物组合疫苗的处方及其制备方法
CN108079286B (zh) 2018-01-19 2020-07-31 云南沃森生物技术股份有限公司 一种13价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
KR102486891B1 (ko) 2018-02-05 2023-01-10 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
SG11202006387QA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN111787944A (zh) 2018-03-05 2020-10-16 武汉博沃生物科技有限公司 一种肺炎链球菌疫苗及其制备方法
KR20190121713A (ko) 2018-04-18 2019-10-28 에스케이바이오사이언스(주) 스트렙토코커스 뉴모니애 협막 다당류 및 그의 면역원성 접합체
CN112041435B (zh) 2018-04-30 2024-05-31 默沙东有限责任公司 提供冻干的突变白喉毒素在二甲基亚砜中的均质溶液的方法
WO2019212842A1 (fr) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Procédés de production de conjugués protéine porteuse-polysaccharide capsulaire de streptococcus pneumoniae à partir de lyosphères
CN112074293B (zh) 2018-04-30 2025-07-11 默沙东有限责任公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
EP3791121A4 (fr) 2018-05-07 2022-01-05 Merck Sharp & Dohme Corp. Sac de lyophilisation
CN108339115B (zh) 2018-05-11 2020-07-10 武汉博沃生物科技有限公司 使用重组载体蛋白的肺炎球菌联合疫苗及其制备方法
WO2019220304A1 (fr) 2018-05-14 2019-11-21 Tergene Biotech Pvt. Ltd. Vaccin conjugué de polysaccharide pneumococcique 15-valent
EP3801469A4 (fr) 2018-06-07 2022-03-09 Merck Sharp & Dohme Corp. Kit de réactifs critiques sous forme de lyosphères
CN108524926B (zh) 2018-06-29 2021-06-29 康希诺生物股份公司 一种多价肺炎球菌结合疫苗的制剂组合及其应用
WO2020009462A1 (fr) 2018-07-06 2020-01-09 주식회사 유바이오로직스 Composition immunogène multivalente comprenant des conjugués polysaccharide-protéine et vaccin la comprenant pour prévenir une maladie provoquée par streptococcus pneumoniae
CN108543066A (zh) 2018-07-17 2018-09-18 成都安特金生物技术有限公司 一种24价肺炎球菌多糖疫苗及其鉴别方法
US12318437B2 (en) 2018-07-21 2025-06-03 Biological E Limited Vaccine formulations comprising preservative
BR112021005425A2 (pt) 2018-09-23 2021-06-15 Biological E Limited polissacarídeos capsulares purificados de streptococcus pneumoniae
SG11202106179VA (en) 2018-10-12 2021-07-29 Biological E Ltd Multivalent pneumococcal polysaccharide-protein conjugate vaccine
CN109336989B (zh) 2018-10-22 2022-05-13 北京智飞绿竹生物制药有限公司 一种通过粘度控制制备肺炎球菌荚膜多糖的方法
CA3120922A1 (fr) 2018-12-12 2020-06-18 Pfizer Inc. Conjugues polysaccharide-proteine immunogenes a heteroantigenes multiples et leurs utilisations
KR20240169145A (ko) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
WO2020152706A1 (fr) 2019-01-21 2020-07-30 Biological E Limited Compositions de vaccins pneumococciques conjugués polyvalents
WO2020157772A1 (fr) 2019-01-28 2020-08-06 Biological E Limited Compositions vaccinales à base de conjugués polysaccharide-protéine pneumococcique multivalentes
CN109771640A (zh) 2019-02-28 2019-05-21 北京智飞绿竹生物制药有限公司 多价肺炎球菌结合疫苗
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
BR112021024491A8 (pt) 2019-06-05 2023-04-11 Merck Sharp & Dohme Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição
KR20220017996A (ko) 2019-06-05 2022-02-14 머크 샤프 앤드 돔 코포레이션 면역원성 혈청형 35b 폐렴구균 폴리사카라이드-단백질 접합체 및 그를 제조하기 위한 접합 방법
CN110302375A (zh) 2019-06-27 2019-10-08 康希诺生物股份公司 一种糖缀合物及其用途
MY207971A (en) 2019-07-18 2025-03-31 Celltrion Inc Immunogenic composition comprising multivalent streptococcus pneumoniae polysaccharide-protein conjugates
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
CN111821432B (zh) 2020-08-05 2022-10-18 北京智飞绿竹生物制药有限公司 一种多价肺炎球菌结合疫苗

Also Published As

Publication number Publication date
MX2021007496A (es) 2021-08-05
CA3123414A1 (fr) 2020-06-25
JP7275277B2 (ja) 2023-05-17
DOP2021000127A (es) 2021-07-30
ECSP21044606A (es) 2021-07-30
AU2019401535A1 (en) 2021-07-22
CN113453708B (zh) 2025-02-21
PH12021551448A1 (en) 2021-12-06
KR102735230B1 (ko) 2024-11-29
GEAP202415690A (en) 2024-01-10
BR112021011961A8 (pt) 2023-02-07
JP2025011236A (ja) 2025-01-23
TW202038996A (zh) 2020-11-01
US20220296695A1 (en) 2022-09-22
WO2020131763A3 (fr) 2020-07-30
KR20240169145A (ko) 2024-12-02
US20240382576A1 (en) 2024-11-21
CN113453708A (zh) 2021-09-28
SG11202106541WA (en) 2021-07-29
GEP20247633B (en) 2024-06-25
JP7778885B2 (ja) 2025-12-02
US20200197503A1 (en) 2020-06-25
JP2022515098A (ja) 2022-02-17
JP2023100823A (ja) 2023-07-19
CO2021008023A2 (es) 2021-07-19
ZA202104162B (en) 2023-12-20
US12016914B2 (en) 2024-06-25
PE20211888A1 (es) 2021-09-22
JP7488938B2 (ja) 2024-05-22
BR112021011961A2 (pt) 2021-09-08
WO2020131763A2 (fr) 2020-06-25
TWI788610B (zh) 2023-01-01
UA130252C2 (uk) 2025-12-31
JOP20210148A1 (ar) 2023-01-30
KR20210104793A (ko) 2021-08-25
CR20210333A (es) 2021-08-18
IL283896A (en) 2021-07-29
CL2021001572A1 (es) 2021-12-24
AU2019401535B2 (en) 2023-12-14
AU2024201265A1 (en) 2024-03-14
IL283896B1 (en) 2026-01-01
NI202100050A (es) 2021-12-06
CN119971019A (zh) 2025-05-13
US20230338498A1 (en) 2023-10-26
US11642406B2 (en) 2023-05-09
JP2023100822A (ja) 2023-07-19
US20230277644A1 (en) 2023-09-07
EP3897705A2 (fr) 2021-10-27

Similar Documents

Publication Publication Date Title
MA54533A (fr) Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
MA51049A (fr) Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
EP3589314A4 (fr) Amélioration de l'immunogénicité de conjugués de polysaccharide de streptococcus pneumoniae et de protéine
EP3758671A4 (fr) 1,2-alcanediols naturels, compositions comportant des 1,2-alcanediols naturels et leurs procédés de préparation
EP3959318A4 (fr) Compositions d'oligonucléotides et leurs méthodes d'utilisation
EP3758729A4 (fr) Conjugués d'il-15 et leurs utilisations
EP3801551A4 (fr) Compositions comprenant des composés bisfluoroalkyl-1,4-benzodiazépinone et des agents immunothérapeutiques et leurs méthodes d'utilisation
EP3801065A4 (fr) Compositions bactériennes spécifiques et leurs utilisations
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
EP3880685A4 (fr) Inhibiteurs d'arg1 et/ou d'arg2
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
FR2912310B1 (fr) Nouvelles compositions cosmetiques et/ou pharmaceutiques et leurs applications.
EP3880688A4 (fr) Préparations et compositions d'oligosaccharides
EP3634390A4 (fr) Compositions antimicrobiennes comprenant des cannabinoïdes et leurs méthodes d'utilisation
EP3684369A4 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
MA54148A (fr) Mélanges et compositions comprenant de la 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one et leurs procédés d'utilisation
EP3955902A4 (fr) Compositions en aérosol comprenant des mitochondries et leurs méthodes d'utilisation
EP4313002A4 (fr) Compositions de polynucléotides, formulations associées et leurs méthodes d'utilisation
EP3836971A4 (fr) Conjugués et leurs procédés d'utilisation
EP3644745A4 (fr) Compositions d'édulcorants oraux et méthodes associées
EP3648603A4 (fr) Compositions antimicrobiennes, désinfectantes et cicatrisantes et leurs procédés de production et d'utilisation
EP3334459A4 (fr) Compositions de liaison à dpep-1 et leurs méthodes d'utilisation
EP4308703A4 (fr) Compositions de polynucléotides, formulations associées et leurs méthodes d'utilisation
EP3672581A4 (fr) Compositions d'amantadine, leurs préparation, et procédés d'utilisation